Zoetis, Inc. (ZTS)
75.81
-0.48
(-0.63%)
USD |
NYSE |
Sep 04, 16:00
75.74
-0.07
(-0.09%)
Pre-Market: 20:00
Zoetis Research and Development Expense (Quarterly) : 173.00M for June 30, 2026
Research and Development Expense (Quarterly) Chart
Sep '18
Jan '19
May '19
285.00
270.00
255.00
240.00
Historical Research and Development Expense (Quarterly) Data
| Date | Value |
|---|---|
| June 30, 2026 | 173.00M |
| March 31, 2026 | 180.00M |
| December 31, 2025 | 199.00M |
| September 30, 2025 | 170.00M |
| June 30, 2025 | 166.00M |
| March 31, 2025 | 162.00M |
| December 31, 2024 | 186.00M |
| September 30, 2024 | 167.00M |
| June 30, 2024 | 171.00M |
| March 31, 2024 | 162.00M |
| December 31, 2023 | 174.00M |
| September 30, 2023 | 152.00M |
| June 30, 2023 | 146.00M |
| March 31, 2023 | 142.00M |
| December 31, 2022 | 148.00M |
| September 30, 2022 | 134.00M |
| June 30, 2022 | 135.00M |
| March 31, 2022 | 122.00M |
| December 31, 2021 | 138.00M |
| September 30, 2021 | 132.00M |
| June 30, 2021 | 120.00M |
| March 31, 2021 | 118.00M |
| December 31, 2020 | 133.00M |
| September 30, 2020 | 112.00M |
| June 30, 2020 | 111.00M |
| Date | Value |
|---|---|
| March 31, 2020 | 107.00M |
| December 31, 2019 | 132.00M |
| September 30, 2019 | 112.00M |
| June 30, 2019 | 111.00M |
| March 31, 2019 | 102.00M |
| December 31, 2018 | 125.00M |
| September 30, 2018 | 108.00M |
| June 30, 2018 | 102.00M |
| March 31, 2018 | 97.00M |
| December 31, 2017 | 110.00M |
| September 30, 2017 | 96.00M |
| June 30, 2017 | 86.00M |
| March 31, 2017 | 90.00M |
| December 31, 2016 | 108.00M |
| September 30, 2016 | 90.00M |
| June 30, 2016 | 88.00M |
| March 31, 2016 | 90.00M |
| December 31, 2015 | 109.00M |
| September 30, 2015 | 91.00M |
| June 30, 2015 | 84.00M |
| March 31, 2015 | 80.00M |
| December 31, 2014 | 124.00M |
| September 30, 2014 | 93.00M |
| June 30, 2014 | 92.00M |
| March 31, 2014 | 87.00M |
R&D Expense Definition
R&D expense is a line item from many companies' income statements.
Research and Development Expense (Quarterly) Range, Past 5 Years
--
Minimum
--
Maximum
--
Average
--
Median
Research and Development Expense (Quarterly) Benchmarks
| Merck & Co., Inc. | 9.229B |
| Phibro Animal Health Corp. | -- |
| Pfizer Inc. | 2.746B |
| Elanco Animal Health, Inc. | 92.00M |
| Boston Scientific Corp. | 554.00M |